Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer

被引：0
|
作者：
Rademaker-Lakhai, JM
Horenblas, S
Meinhardt, W
Stokvis, E
De Reijke, TM
Jimeno, JM
Lazaro, LL
Martin, JAL
Beijnen, JH
Schellens, JHM
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[3] Pharmamar SA, Madrid, Spain
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2003年 / 56卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：469 / 469
页数：1
相关论文
共 50 条
  • [31] Clinical and pharmacokinetic phase I dose-finding study of kahalalide F (KF) administered as a prolonged infusion in patients with solid tumors.
    Salazar, R
    Casado, E
    Martin, AL
    Pardo, B
    Roca, JM
    Rodriguez, R
    Garcia, M
    Tabernero, J
    Heras, BDL
    Paz-Ares, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 149S - 149S
  • [32] A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer
    Meropol, NJ
    Rustum, YM
    Petrelli, NJ
    RodriguezBigas, M
    Frank, C
    Ho, DH
    Kurowski, M
    Creaven, PJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (06) : 581 - 586
  • [33] A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer
    Dumez, Herlinde
    Gall, Helen
    Capdeville, Renaud
    Dutreix, Catherine
    van Oosterom, Allan T.
    Giaccone, Giuseppe
    ANTI-CANCER DRUGS, 2007, 18 (02) : 219 - 225
  • [34] PHASE-I PHARMACOKINETIC STUDY OF THE METHOTREXATE ANALOG, TRIMETREXATE, IN PATIENTS WITH ADVANCED CANCER
    MORRIS, RG
    REECE, PA
    BISHOP, JF
    OLVER, IN
    RAGHAVAN, D
    MEDICAL AND PEDIATRIC ONCOLOGY, 1987, 15 (03): : 124 - 124
  • [35] A phase I pharmacokinetic study of declopramide in combination with cisplatin in patients with advanced cancer.
    Remick, S
    Dowlati, A
    Robertson, K
    Buchter, C
    Ingalls, S
    Hoppel, C
    Spiro, T
    Makkar, V
    Overmoyer, B
    Gerson, S
    ANNALS OF ONCOLOGY, 2000, 11 : 138 - 138
  • [36] A RANDOMIZED PHASE II STUDY OF IPILIMUMAB WITH ANDROGEN ABLATION COMPARED WITH ANDROGEN ABLATION ALONE IN PATIENTS WITH ADVANCED PROSTATE CANCER
    Tollefson, Matthew
    Karnes, R. Jeffrey
    Thompson, R. Houston
    Granberg, Candace
    Hillman, David
    Breau, Rodney
    Allison, James
    Kwon, Eugene
    Blute, Michael
    JOURNAL OF UROLOGY, 2010, 183 (04): : E261 - E261
  • [37] A phase I dose escalation and expansion study of HPN424, a PSMA-targeting T cell engager, in patients with advanced prostate cancer refractory to androgen therapy
    Bendell, Johanna
    Stein, Mark
    de Bono, Johann
    Austin, Richard
    Hirabayashi, Sue
    Law, Che-Leung
    Lemon, Bryan
    Wesche, Holger
    Weitzman, Aaron
    Fong, Lawrence
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [38] A Phase I/II Study of Trimetrexate and Capecitabine in Patients With Advanced Refractory Colorectal Cancer
    Matin, K
    Jacobs, SA
    Richards, T
    Wong, MK
    Earle, M
    Evans, T
    Troetschel, M
    Ferri, W
    Friedland, D
    Pinkerton, R
    Volkin, R
    Wieand, S
    Ramanathan, RK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (05): : 439 - 444
  • [39] A phase I study of paclitaxel/doxorubicin/thalidomide in patients with androgen-independent prostate cancer
    Amato, Robert J.
    Sarao, Harmeet
    CLINICAL GENITOURINARY CANCER, 2006, 4 (04) : 281 - 286
  • [40] Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    Minami, Hironobu
    Kawada, Kenji
    Ebi, Hiromichi
    Kitagawa, Koichi
    Kim, Yon-il
    Araki, Kazuhiro
    Mukai, Hirofumi
    Tahara, Makoto
    Nakajima, Hikaru
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (07): : 1492 - 1498
12345